The UK ATTR Amyloidosis Patients’ Association (UKATPA) was founded in 2017 by a group of UK patients with transthyretin (TTR)-type systemic amyloidosis (ATTR), supported by the consultant physicians of the UK NHS National Amyloidosis Centre. In recent years there have been major advances in the field of ATTR amyloidosis....
All patients with suspected or diagnosed ATTR amyloidosis should be assessed in a dedicated specialist unit. In the UK, the referral centre is the NHS National Amyloidosis Centre (NAC) at the Royal Free Hospital, London. Information for referring physicians in… Read MoreLearn More
Information about the UK ATTR Amyloidosis Patients Association (UKAPTA) The UK National Amyloidosis Centre Amyloidosis Awareness Programme has provided extensive patient information and support since 2013. Resources of interest to patients with ATTR amyloidosis include: NAC resources: Information… Read MoreLearn More
In recent years effective new drugs for ATTR amyloidosis have become available. These drugs can improve symptoms and delay disease progression in suitable patients. Several other drugs are in various stages of development, offering yet more hope for the future. The trials discussed below are ongoing at the London National Amyloidosis Centre. For more details on each trial, see clinicaltrials.govRead More